Xenetic Biosciences, Inc.
Xenetic Biosciences develops a proprietary DNase technology targeting neutrophil extracellular traps to enhance immunotherapy outcomes in cancer.
8-KSep 23Latest SEC filing, period to Sep 23
Sep 16Latest story
September 2026
August 2026